Categories AlphaGraphs, Health Care

Infographic: Highlights from Gilead Sciences (GILD) Q2 2020 earnings

Gilead Sciences (NASDAQ: GILD) reported second-quarter financial results after the closing bell on Thursday. The biotechnology firm missed both the revenue and earnings estimates for the quarter.

GILD shares fell over 2% immediately following the announcement. The stock has gained 11% since the beginning of this year.

GIlead sciences Q2 2020 earnings

Looking forward to listening to management/ analysts comments on Q2 results? Stay tuned here for Gilead Science Q2 2020 earnings call transcript

CEO Daniel O’Day said, “We are also making important progress with our pipeline. In addition to the critical work of advancing remdesivir, we have continued to strengthen our presence in immuno-oncology. This includes six immuno-oncology agreements this year and the recent FDA approval for TecartusTM in mantle cell lymphoma.”

Prior performance

[irp posts=”67604″]

____

Most Popular

NFLX Stock: Should you invest in Netflix ahead of upcoming earnings?

For a large number of people, streaming videos and TV shows are the first preference when they want to keep themselves engaged during the lockdown. Streaming giant Netflix, Inc. (NASDAQ:

Earnings: Citigroup (C) Q4 profit beats estimates; revenue edges up

Citigroup Inc. (NYSE: C) on Friday said its fourth-quarter profit decreased despite modest growth in revenues. However, the numbers topped the market’s projections. Fourth-quarter net profit declined to $3.2 billion

JPM Earnings: All you need to know about JPMorgan Chase’s Q4 2021 earnings results

JPMorgan Chase & Co. (NYSE: JPM) reported fourth-quarter 2021 earnings results today. Reported revenue was flat year-over-year to $29.3 billion. Net income decrease 12% to $12.1 billion while EPS decreased

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top